Skip to main content

Month: May 2022

Amdocs Launches Americas 5G Experience Lab to Rapidly Unleash Network Innovation in the 5G Era

5G Experience Lab will capitalize on a diverse partner ecosystem to unlock new applications and services for our increasingly connected digital society JERSEY CITY, N.J., May 05, 2022 (GLOBE NEWSWIRE) — Amdocs (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today announced the opening of its Americas 5G Experience Lab in Dallas, Texas. This lab will enable creative organizations serving our connected society to come together and create innovative services leveraging the power of 5G networks. The broader monetization potential of 5G lies in the ability to leverage its capabilities in different ways. This includes onboarding partner applications, slicing the network for enterprises and application providers and enabling software developers to reimagine–the “one size fits all” experiences...

Continue reading

MIMEDX to Participate at Upcoming Investor Conferences

MARIETTA, Ga., May 05, 2022 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will participate in the following investor conferences:Bank of America Securities 2022 Healthcare ConferenceFireside Chat: Tuesday, May 10, 2022 at 12:15 PM PT / 3:15 PM ETWebcast: Click here to accessH.C. Wainwright Global Investment ConferenceFireside Chat: Tuesday, May 24, 2022 at 10:00 AM ETWebcast: Click here to accessInstitutional investors interested in meeting with senior management may contact their respective Bank of America or H.C. Wainwright representative. A live webcast of both fireside chats will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com or through the conference...

Continue reading

ConnectOne Bank Announces Partnership with Nymbus to Build Bespoke Banking Solution

ENGLEWOOD CLIFFS, N.J., May 05, 2022 (GLOBE NEWSWIRE) — ConnectOne Bank (“ConnectOne”), the insured depository subsidiary of ConnectOne Bancorp, Inc. (NASDAQ: CNOB), announced today its partnership with Nymbus, a cloud-native platform and leading provider of banking technology solutions and core services, to offer digital business banking solutions. “Since inception, ConnectOne Bank’s mission has been to offer our clients best-in-class banking experiences tailored to their unique needs. As we diversify our client roster, partnering with Nymbus allows us to continue that mission by building a niche-based vertical powered by leading technology,” said Frank Sorrentino III, Chairman & CEO of ConnectOne Bank. “We look forward to working with Nymbus to extend our mission into new segments.” This partnership adds another layer to...

Continue reading

Zscaler to Host Third Quarter Fiscal Year 2022 Earnings Conference Call

Earnings Results to be Released on Thursday, May 26, After the Close of the Market SAN JOSE, Calif., May 05, 2022 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, will release third quarter fiscal year 2022 earnings after the market closes on Thursday, May 26, 2022. The company will host an investor conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the results.  Date: Thursday, May 26, 2022  Time: 1:30 p.m. PT  Webcast: https://ir.zscaler.com  Dial-in number: 918-922-3018Please dial in at least 10 minutes prior to the 1:30 p.m. PT start time. A live webcast of the conference call will be accessible from the Zscaler website at ir.zscaler.com. Listeners may log on to the call under the “Events & Presentations” section and select “Q3 2022 Zscaler...

Continue reading

Battalion Oil Corporation Announces First Quarter 2022 Earnings Release and Conference Call Schedule

HOUSTON, TX, May 05, 2022 (GLOBE NEWSWIRE) — Battalion Oil Corporation (NYSE American: BATL, “Battalion” or the “Company”) today announced plans to release its first quarter 2022 financial results on Monday, May 9, 2022 after trading closes on the New York Stock Exchange. The Company has also scheduled a conference call for Tuesday, May 10, 2022, at 10:00 a.m. Central Time to discuss the release. To access the live conference call, local participants may dial +1 (646) 828-8193. All other participants may dial (888) 220-8474 for toll free. The confirmation code for the live conference call is 2126195. The live conference call will also be available through the Company’s website at www.battalionoil.com on the Events and Presentations page under the Investors tab. The replay for the event will be available on the Company’s website...

Continue reading

American Shared Hospital Services Announces First Quarter 2022 Earnings Conference Call

Conference Call on Thursday, May 12, 2022 at 3:00pm ET / 12:00pm PT San Francisco, CA, May 05, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its first quarter 2022 financial results on May 12, 2022 at 3:00pm ET / 12:00pm PT. The first quarter 2022 financial results press release will be issued premarket the morning of Thursday, May 12, 2022. Teleconference Date/Time Thursday, May 12, 2022 at 3:00pm ET / 12:00pm PT Teleconference and Webcast Information To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the...

Continue reading

Uniti Group Inc. Reports First Quarter 2022 Results

Raises 2022 Outlook First Quarter Consolidated Bookings Increased Over 50% From Prior YearNet Income of $0.21 Per Diluted Common Share for the First Quarter; Increase of $0.23 Per Diluted Common Share from the Prior Year First Quarter Adjusted EBITDA and AFFO Grew 4.9% and 9.0% for the First Quarter, Respectively, from the Prior Year First Quarter AFFO Per Diluted Common Share of $0.43 for the First QuarterLITTLE ROCK, Ark., May 05, 2022 (GLOBE NEWSWIRE) — Uniti Group Inc. (“Uniti” or the “Company”) (Nasdaq: UNIT) today announced its results for the first quarter 2022. “The demand for our mission critical communications infrastructure remains very strong as evidenced by the fourth consecutive quarter of elevated new consolidated bookings, a 58% increase over the first quarter of 2021. We also continue to demonstrate the shared...

Continue reading

Protara Therapeutics Announces First Quarter 2022 Financial Results and Business Overview

– Patient Dosing Underway in Phase 1 ADVANCED-1 Study of TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer – – Strong Cash, Cash Equivalents and Investments Position of $119M as of March 31, 2022 Expected to Fund Operations into Mid-2024 – NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2022 and provided a business update. “The recent commencement of patient dosing in the Phase 1 ADVANCED-1 trial of TARA-002 for non-muscle invasive bladder cancer (NMIBC) marked an important step toward our goal of bringing a much needed, novel therapeutic option to this underserved population,”...

Continue reading

BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones

—Q1 2022 ORLADEYO net revenue of $49.7 million— —ORLADEYO net revenue in 2022 expected to be no less than $250 million— —Company provides update on BCX9930 investigation— RESEARCH TRIANGLE PARK, N.C., May 05, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2022, and provided a corporate update. “We are now over a year into the ORLADEYO launch and are excited to see strong and continuing patient demand and steady expansion in our prescriber base among both new and existing prescribers. These trends continued in the first quarter of 2022 and reinforce our confidence that we will achieve no less than $250 million in net ORLADEYO revenue in 2022 and peak ORLADEYO sales of $1 billion,” said Jon Stonehouse, president and chief executive officer...

Continue reading

Alzheimer’s Drugs Market Size [2022-2028] | Industry Size, Share, Growth, Trends & Forecast Analysis

Key Prominent Players Covered in the Alzheimer’s Drugs Market Research Report Are Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company., Merck Sharp & Dohme Corp., AstraZeneca, Biogen, AbbVie Inc., ALLERGAN, other players Pune, India, May 05, 2022 (GLOBE NEWSWIRE) — Increasing prevalence of Alzheimer’s disease is fueling the demand for Alzheimer’s drugs which in turn is driving the global Alzheimer’s drugs market, says Fortune Business Insights in a report, titled Alzheimer’s Drugs Market Size , Share and Global Trend By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Antagonist, Combination Drugs, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast till 2026. Rising R&D activities by pharmaceutical companies and research...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.